Fig. 4: Rab5a mediates the early internalization of EGFR in macrophages.

A–C BMDM were treated with LPS (1 µg/mL) for 1 h with or without PD168393 (PD 10 μM) pretreatment for 30 min. A Immune-staining of EGFR and EEA1 in BMDM. B Immune-staining of EGFR with Rab5a. C Co-immunoprecipitation between EGFR and Rab5a in BMDM. D–F BMDM transfected with si-NC or si-Rab5a for 48 h followed by LPS treatment (1 µg/mL) for 1 h. D EGFR expression on the surface of BMDM was analyzed by flow cytometry. E Percentage of EGFR-positive BMDM is shown (n = 3). F Mean fluorescence intensity (MFI) is shown (n = 3). G–I BMDM were treated with LPS (1 µg/mL) for 1 h, with or without clathrin inhibitor chlorpromazine (CPZ 12.5 μM) or PD168393 (PD 10 μM) pretreatment for 30 min. G EGFR expression on the surface of BMDM was analyzed by flow cytometry (n = 3). H Percentage of EGFR-positive BMDM is shown (n = 3). I Mean fluorescence intensity (MFI) is shown (n = 3). J–L WT and Rab5a−/− BMDM were treated with LPS (1 μg/mL) for 1 h. J EGFR expression on the surface of BMDM was analyzed by flow cytometry (n = 3). K Percentage of EGFR-positive BMDM is shown (n = 3). L Mean fluorescence intensity (MFI) is shown (n = 3). The graphs depict mean ± SD based on three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.